Testing effectiveness (Phase 2)Ended earlyNCT05328102
What this trial is testing
Phase 2 Study of Plamotamab Combined With Tafasitamab Plus Lenalidomide Versus Tafasitamab Plus Lenalidomide in Relapsed or Refractory (R/R) Diffuse Large-cell B-cell Lymphoma (DLBCL)
Who this might be right for
Diffuse Large-cell B-cell Lymphoma
Xencor, Inc. 3